XC8 in the Treatment of Patients With Acute Respiratory Viral Infection

NCT03441373 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Acute Respiratory Infection

Interventions

DRUG: XC8 20 mg
DRUG: XC8 100 mg
DRUG: XC8 200 mg
DRUG: Placebo

Sponsor

PHARMENTERPRISES LLC